{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:03:31Z","timestamp":1790795011425,"version":"4.1.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2009,11,1]],"date-time":"2009-11-01T00:00:00Z","timestamp":1257033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2009,11]]},"DOI":"10.1016\/j.amjcard.2009.09.017","type":"journal-article","created":{"date-parts":[[2009,11,5]],"date-time":"2009-11-05T12:30:55Z","timestamp":1257424255000},"page":"32E-38E","source":"Crossref","is-referenced-by-count":53,"special_numbering":"S","title":["The Pharmacology and Off-Target Effects of Some Cholesterol Ester Transfer Protein Inhibitors"],"prefix":"10.1016","volume":"104","author":[{"given":"Menno","family":"Vergeer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik S.G.","family":"Stroes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2009.09.017_bib1","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/ncpcardio0768","article-title":"Mechanisms of disease: HDL metabolism as a target for novel therapies","volume":"4","author":"Rader","year":"2007","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"10.1016\/j.amjcard.2009.09.017_bib2","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1161\/01.ATV.0000054658.91146.64","article-title":"Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis","volume":"23","author":"Barter","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.amjcard.2009.09.017_bib3","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1172\/JCI118751","article-title":"Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels","volume":"97","author":"Zhong","year":"1996","journal-title":"J Clin Invest"},{"key":"10.1016\/j.amjcard.2009.09.017_bib4","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1194\/jlr.M300520-JLR200","article-title":"A prospective study of HDL-C and cholesteryl ester transfer protein gene mutations and the risk of coronary heart disease in the elderly","volume":"45","author":"Curb","year":"2004","journal-title":"J Lipid Res"},{"key":"10.1016\/j.amjcard.2009.09.017_bib5","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1161\/01.ATV.17.6.1053","article-title":"Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan: marked hyperalphalipoproteinemia caused by CETP gene mutation is not associated with longevity","volume":"17","author":"Hirano","year":"1997","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.amjcard.2009.09.017_bib6","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1001\/jama.299.23.2777","article-title":"Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk","volume":"299","author":"Thompson","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2009.09.017_bib7","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1517\/13543784.17.10.1589","article-title":"JTT-705: is there still future for a CETP inhibitor after torcetrapib?","volume":"17","author":"Rennings","year":"2008","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.amjcard.2009.09.017_bib8","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1161\/01.ATV.19.4.1105","article-title":"Increased atherosclerosis in ApoE and LDL receptor gene knock-out mice as a result of human cholesteryl ester transfer protein transgene expression","volume":"19","author":"Plump","year":"1999","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.amjcard.2009.09.017_bib9","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1161\/01.ATV.0000243925.65265.3c","article-title":"Cholesteryl ester transfer protein decreases high-density lipoprotein and severely aggravates atherosclerosis in APOE*3-Leiden mice","volume":"26","author":"Westerterp","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.amjcard.2009.09.017_bib10","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1038\/70956","article-title":"Spontaneous combined hyperlipidemia, coronary heart disease and decreased survival in Dahl salt-sensitive hypertensive rats transgenic for human cholesteryl ester transfer protein","volume":"5","author":"Herrera","year":"1999","journal-title":"Nat Med"},{"key":"10.1016\/j.amjcard.2009.09.017_bib11","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1172\/JCI118255","article-title":"Decreased early atherosclerotic lesions in hypertriglyceridemic mice expressing cholesteryl ester transfer protein transgene","volume":"96","author":"Hayek","year":"1995","journal-title":"J Clin Invest"},{"key":"10.1016\/j.amjcard.2009.09.017_bib12","doi-asserted-by":"crossref","first-page":"36912","DOI":"10.1074\/jbc.274.52.36912","article-title":"Cholesteryl ester transfer protein corrects dysfunctional high density lipoproteins and reduces aortic atherosclerosis in lecithin cholesterol acyltransferase transgenic mice","volume":"274","author":"Foger","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/j.amjcard.2009.09.017_bib13","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1161\/01.ATV.0000259357.42089.dc","article-title":"Cholesteryl ester transfer protein (CETP) expression protects against diet induced atherosclerosis in SR-BI deficient mice","volume":"27","author":"Harder","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.amjcard.2009.09.017_bib14","doi-asserted-by":"crossref","first-page":"5033","DOI":"10.1074\/jbc.273.9.5033","article-title":"Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits","volume":"273","author":"Sugano","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1016\/j.amjcard.2009.09.017_bib15","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1161\/01.ATV.20.9.2106","article-title":"Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis","volume":"20","author":"Rittershaus","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.amjcard.2009.09.017_bib16","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/35018119","article-title":"A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits","volume":"406","author":"Okamoto","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.amjcard.2009.09.017_bib17","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","article-title":"Effects of torcetrapib in patients at high risk for coronary events","volume":"357","author":"Barter","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2009.09.017_bib18","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1161\/01.CIR.0000015857.31889.7B","article-title":"Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study","volume":"105","author":"de Grooth","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2009.09.017_bib19","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.amjcard.2004.12.064","article-title":"Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia","volume":"95","author":"Kuivenhoven","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2009.09.017_bib20","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1056\/NEJMoa031766","article-title":"Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol","volume":"350","author":"Brousseau","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2009.09.017_bib21","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1161\/01.ATV.0000118278.21719.17","article-title":"Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib","volume":"24","author":"Clark","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.amjcard.2009.09.017_bib22","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1016\/j.jacc.2006.06.066","article-title":"Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin","volume":"48","author":"McKenney","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2009.09.017_bib23","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1016\/j.jacc.2006.06.067","article-title":"Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels","volume":"48","author":"Davidson","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2009.09.017_bib24","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0140-6736(07)61088-5","article-title":"Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial","volume":"370","author":"Bots","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2009.09.017_bib25","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1056\/NEJMoa071359","article-title":"Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia","volume":"356","author":"Kastelein","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2009.09.017_bib26","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1056\/NEJMoa070635","article-title":"Effect of torcetrapib on the progression of coronary atherosclerosis","volume":"356","author":"Nissen","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2009.09.017_bib27","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1161\/ATVBAHA.107.151688","article-title":"Inhibition of CETP by torcetrapib attenuates the atherogenicity of postprandial TG-rich lipoproteins in type IIB hyperlipidemia","volume":"28","author":"Guerin","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.amjcard.2009.09.017_bib28","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/clpt.2008.109","article-title":"Multiple-dose pharmacodynamics and pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects","volume":"84","author":"Krishna","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.amjcard.2009.09.017_bib29","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/S0140-6736(07)61813-3","article-title":"Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies","volume":"370","author":"Krishna","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2009.09.017_bib30","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ahj.2008.09.022","article-title":"Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients","volume":"157","author":"Bloomfield","year":"2009","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjcard.2009.09.017_bib31","doi-asserted-by":"crossref","first-page":"3566","DOI":"10.1021\/jm000224s","article-title":"bis(2-(Acylamino)phenyl) disulfides, 2-(acylamino)benzenethiols, and S-(2-(acylamino)phenyl) alkanethioates as novel inhibitors of cholesteryl ester transfer protein","volume":"43","author":"Shinkai","year":"2000","journal-title":"J Med Chem"},{"key":"10.1016\/j.amjcard.2009.09.017_bib32","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1042\/cs1030587","article-title":"Cholesteryl ester transfer protein inhibitor (JTT-705) and the development of atherosclerosis in rabbits with severe hypercholesterolaemia","volume":"103","author":"Huang","year":"2002","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.amjcard.2009.09.017_bib33","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1194\/jlr.M500349-JLR200","article-title":"Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action","volume":"47","author":"Clark","year":"2006","journal-title":"J Lipid Res"},{"key":"10.1016\/j.amjcard.2009.09.017_bib34","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1194\/jlr.M600332-JLR200","article-title":"Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand White rabbits","volume":"48","author":"Morehouse","year":"2007","journal-title":"J Lipid Res"},{"key":"10.1016\/j.amjcard.2009.09.017_bib35","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1161\/CIRCULATIONAHA.107.761965","article-title":"Torcetrapib does not reduce atherosclerosis beyond atorvastatin and induces more proinflammatory lesions than atorvastatin","volume":"117","author":"de Haan","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2009.09.017_bib36","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1161\/01.ATV.0000118278.21719.17","article-title":"Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib","volume":"24","author":"Clark","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.amjcard.2009.09.017_bib37","series-title":"Identification and characterization of MK-0859, a novel cholesteryl ester transfer protein inhibitor","author":"O'Neill","year":"2007"},{"key":"10.1016\/j.amjcard.2009.09.017_bib38","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1161\/CIRCULATIONAHA.108.772665","article-title":"Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials","volume":"118","author":"Vergeer","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2009.09.017_bib39","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1161\/CIRCULATIONAHA.108.790733","volume":"118","author":"Nicholls","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2009.09.017_bib40","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1038\/bjp.2008.229","article-title":"Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone","volume":"154","author":"Forrest","year":"2008","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.amjcard.2009.09.017_bib41","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1210\/en.2008-1512","article-title":"Torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition","volume":"150","author":"Hu","year":"2009","journal-title":"Endocrinology"},{"issue":"suppl 1","key":"10.1016\/j.amjcard.2009.09.017_bib42","first-page":"A322","article-title":"Absence of effect of R1658\/JTT-705 on blood pressure and tissue expression of renin-angiotensin system related genes in rats [abstract]","volume":"51","author":"Stroes","year":"2008","journal-title":"J Am Coll Cardiol"},{"issue":"suppl 1","key":"10.1016\/j.amjcard.2009.09.017_bib43","first-page":"A333","article-title":"Safety profile of the cholesteryl ester transfer protein inhibitor R1658\/JTT-705 in patients with type II hyperlipidemia or coronary heart disease [abstract]","volume":"51","author":"Stein","year":"2008","journal-title":"J Am Coll Cardiol"},{"issue":"suppl 1","key":"10.1016\/j.amjcard.2009.09.017_bib44","first-page":"A333","article-title":"Cardiovascular safety of the cholesteryl ester transfer protein inhibitor R1658\/JTT-705: results from phase 2 trials [abstract]","volume":"51","author":"Steiner","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2009.09.017_bib45","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1210\/en.2009-0136","article-title":"The off-target effects of torcetrapib","volume":"150","author":"Funder","year":"2009","journal-title":"Endocrinology"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914909023789?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914909023789?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T16:24:26Z","timestamp":1558628666000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914909023789"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11]]},"references-count":45,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2009,11]]}},"alternative-id":["S0002914909023789"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2009.09.017","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2009,11]]}}}